These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 24900213)

  • 41. Discovery of SHR1653, a Highly Potent and Selective OTR Antagonist with Improved Blood-Brain Barrier Penetration.
    Li X; Zhang Z; Chen Y; Wan H; Sun J; Wang B; Feng B; Hu B; Shi X; Feng J; Zhang L; He F; Bai C; Zhang L; Tao W
    ACS Med Chem Lett; 2019 Jun; 10(6):996-1001. PubMed ID: 31223461
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The discovery of potent and selective pyridopyrimidin-7-one based inhibitors of B-RafV600E kinase.
    Ren L; Ahrendt KA; Grina J; Laird ER; Buckmelter AJ; Hansen JD; Newhouse B; Moreno D; Wenglowsky S; Dinkel V; Gloor SL; Hastings G; Rana S; Rasor K; Risom T; Sturgis HL; Voegtli WC; Mathieu S
    Bioorg Med Chem Lett; 2012 May; 22(10):3387-91. PubMed ID: 22534450
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 3,4-Disubstituted indole acylsulfonamides: a novel series of potent and selective human EP3 receptor antagonists.
    Zhou N; Zeller W; Krohn M; Anderson H; Zhang J; Onua E; Kiselyov AS; Ramirez J; Halldorsdottir G; Andrésson T; Gurney ME; Singh J
    Bioorg Med Chem Lett; 2009 Jan; 19(1):123-6. PubMed ID: 19022669
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Discovery of BMS-986260, a Potent, Selective, and Orally Bioavailable TGFβR1 Inhibitor as an Immuno-oncology Agent.
    Velaparthi U; Darne CP; Warrier J; Liu P; Rahaman H; Augustine-Rauch K; Parrish K; Yang Z; Swanson J; Brown J; Dhar G; Anandam A; Holenarsipur VK; Palanisamy K; Wautlet BS; Fereshteh MP; Lippy J; Tebben AJ; Sheriff S; Ruzanov M; Yan C; Gupta A; Gupta AK; Vetrichelvan M; Mathur A; Gelman M; Singh R; Kinsella T; Murtaza A; Fargnoli J; Vite G; Borzilleri RM
    ACS Med Chem Lett; 2020 Feb; 11(2):172-178. PubMed ID: 32071685
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 3-(2-Aminocarbonylphenyl)propanoic acid analogs as potent and selective EP3 receptor antagonists. Part 1: discovery and exploration of the carboxyamide side chain.
    Asada M; Obitsu T; Nagase T; Tanaka M; Yamaura Y; Takizawa H; Yoshikawa K; Sato K; Narita M; Ohuchida S; Nakai H; Toda M
    Bioorg Med Chem; 2010 Jan; 18(1):80-90. PubMed ID: 20004584
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Piperidyl amides as novel, potent and orally active mGlu5 receptor antagonists with anxiolytic-like activity.
    Spanka C; Glatthar R; Desrayaud S; Fendt M; Orain D; Troxler T; Vranesic I
    Bioorg Med Chem Lett; 2010 Jan; 20(1):184-8. PubMed ID: 19931453
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Discovery of aryl ureas and aryl amides as potent and selective histamine H3 receptor antagonists for the treatment of obesity (part II).
    Gao Z; Hurst WJ; Guillot E; Czechtizky W; Lukasczyk U; Nagorny R; Pruniaux MP; Schwink L; Sanchez JA; Stengelin S; Tang L; Winkler I; Hendrix JA; George PG
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3421-6. PubMed ID: 23591112
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Discovery of a Novel Highly Selective Histamine H4 Receptor Antagonist for the Treatment of Atopic Dermatitis.
    Ko K; Kim HJ; Ho PS; Lee SO; Lee JE; Min CR; Kim YC; Yoon JH; Park EJ; Kwon YJ; Yun JH; Yoon DO; Kim JS; Park WS; Oh SS; Song YM; Cho WK; Morikawa K; Lee KJ; Park CH
    J Med Chem; 2018 Apr; 61(7):2949-2961. PubMed ID: 29579390
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands.
    Serradeil-Le Gal C; Wagnon J; Valette G; Garcia G; Pascal M; Maffrand JP; Le Fur G
    Prog Brain Res; 2002; 139():197-210. PubMed ID: 12436936
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists.
    Cheng Y; Albrecht BK; Brown J; Buchanan JL; Buckner WH; DiMauro EF; Emkey R; Fremeau RT; Harmange JC; Hoffman BJ; Huang L; Huang M; Lee JH; Lin FF; Martin MW; Nguyen HQ; Patel VF; Tomlinson SA; White RD; Xia X; Hitchcock SA
    J Med Chem; 2008 Aug; 51(16):5019-34. PubMed ID: 18680277
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of PGE2 EP3/EP4 receptors on bladder dysfunction in mice with experimental autoimmune encephalomyelitis.
    Xue R; Jia Z; Kong X; Pi G; Ma S; Yang J
    Am J Physiol Renal Physiol; 2013 Dec; 305(12):F1656-62. PubMed ID: 24154697
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Discovery of Pyrrolidine Sulfonamides as Selective and Orally Bioavailable Antagonists of Transient Receptor Potential Vanilloid-4 (TRPV4).
    Brnardic EJ; Ye G; Brooks C; Donatelli C; Barton L; McAtee J; Sanchez RM; Shu A; Erhard K; Terrell L; Graczyk-Millbrandt G; He Y; Costell MH; Behm DJ; Roethke T; Stoy P; Holt DA; Lawhorn BG
    J Med Chem; 2018 Nov; 61(21):9738-9755. PubMed ID: 30335378
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Discovery of novel N-acylsulfonamide analogs as potent and selective EP3 receptor antagonists.
    Asada M; Obitsu T; Kinoshita A; Nakai Y; Nagase T; Sugimoto I; Tanaka M; Takizawa H; Yoshikawa K; Sato K; Narita M; Ohuchida S; Nakai H; Toda M
    Bioorg Med Chem Lett; 2010 Apr; 20(8):2639-43. PubMed ID: 20346663
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Optimization of alkylidene hydrazide based human glucagon receptor antagonists. Discovery of the highly potent and orally available 3-cyano-4-hydroxybenzoic acid [1-(2,3,5,6-tetramethylbenzyl)-1H-indol-4-ylmethylene]hydrazide.
    Madsen P; Ling A; Plewe M; Sams CK; Knudsen LB; Sidelmann UG; Ynddal L; Brand CL; Andersen B; Murphy D; Teng M; Truesdale L; Kiel D; May J; Kuki A; Shi S; Johnson MD; Teston KA; Feng J; Lakis J; Anderes K; Gregor V; Lau J
    J Med Chem; 2002 Dec; 45(26):5755-75. PubMed ID: 12477359
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Discovery of aryl ureas and aryl amides as potent and selective histamine H3 receptor antagonists for the treatment of obesity (part I).
    Gao Z; Hurst WJ; Guillot E; Czechtizky W; Lukasczyk U; Nagorny R; Pruniaux MP; Schwink L; Sanchez JA; Stengelin S; Tang L; Winkler I; Hendrix JA; George PG
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3416-20. PubMed ID: 23591110
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identification and Optimization of Benzimidazole Sulfonamides as Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists with in Vivo Activity.
    Hennessy EJ; Oza V; Adam A; Byth K; Castriotta L; Grewal G; Hamilton GA; Kamhi VM; Lewis P; Li D; Lyne P; Öster L; Rooney MT; Saeh JC; Sha L; Su Q; Wen S; Xue Y; Yang B
    J Med Chem; 2015 Sep; 58(17):7057-75. PubMed ID: 26291341
    [TBL] [Abstract][Full Text] [Related]  

  • 57. TEI-3356, a highly selective agonist for the prostaglandin EP3 receptor.
    Negishi M; Harazono A; Sugimoto Y; Hazato A; Kurozumi S; Ichikawa A
    Prostaglandins; 1994 Nov; 48(5):275-83. PubMed ID: 7855308
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Benzimidazoles as Potent and Orally Active mGlu5 Receptor Antagonists with an Improved PK Profile.
    Carcache D; Vranesic I; Blanz J; Desrayaud S; Fendt M; Glatthar R
    ACS Med Chem Lett; 2011 Jan; 2(1):58-62. PubMed ID: 24900255
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Discovery of potent, orally-active, and muscle-selective androgen receptor modulators based on an N-aryl-hydroxybicyclohydantoin scaffold.
    Sun C; Robl JA; Wang TC; Huang Y; Kuhns JE; Lupisella JA; Beehler BC; Golla R; Sleph PG; Seethala R; Fura A; Krystek SR; An Y; Malley MF; Sack JS; Salvati ME; Grover GJ; Ostrowski J; Hamann LG
    J Med Chem; 2006 Dec; 49(26):7596-9. PubMed ID: 17181141
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Discovery of highly potent and selective biphenylacylsulfonamide-based beta3-adrenergic receptor agonists and evaluation of physical properties as potential overactive bladder therapies: part 5.
    Hattori K; Toda S; Imanishi M; Itou S; Nakajima Y; Washizuka K; Araki T; Hamashima H; Tomishima Y; Sakurai M; Matsui S; Imamura E; Ueshima K; Yamamoto T; Yamamoto N; Ishikawa H; Nakano K; Unami N; Hamada K; Matsumura Y; Takamura F
    J Med Chem; 2009 May; 52(9):3063-72. PubMed ID: 19366244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.